Peter Lawson
Stock Analyst at Barclays
(3.43)
# 1,112
Out of 4,502 analysts
79
Total ratings
49.28%
Success rate
4.16%
Average return
Main Sectors:
Top Industries:
31 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Overweight | $52 → $54 | $45.56 | +18.53% | 2 | Jul 18, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $20 → $31 | $21.04 | +47.34% | 2 | Jul 15, 2024 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $35 → $25 | $14.98 | +66.89% | 5 | Jul 8, 2024 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $17 | $10.48 | +62.21% | 3 | Jun 7, 2024 | |
| BMEA Biomea Fusion | Downgrades: Equal-Weight | $30 → $5 | $5.46 | -8.42% | 2 | Jun 7, 2024 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $18 → $13 | $9.85 | +31.98% | 1 | May 24, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $25 → $14 | $5.50 | +154.55% | 6 | May 10, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Overweight | $15 | $9.06 | +65.56% | 3 | May 10, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $70 → $75 | $113.69 | -34.03% | 8 | May 3, 2024 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $25 | $22.96 | +8.89% | 4 | Apr 11, 2024 | |
| TCRX TScan Therapeutics | Maintains: Overweight | $7 → $9 | $7.18 | +25.35% | 1 | Mar 7, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $60 | $29.52 | +103.25% | 5 | Feb 29, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $22 | $9.43 | +133.30% | 4 | Feb 29, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Overweight | $47 → $63 | $36.87 | +70.87% | 3 | Feb 29, 2024 | |
| FATE Fate Therapeutics | Maintains: Overweight | $6 → $10 | $5.40 | +85.19% | 3 | Feb 27, 2024 | |
| EXAI Exscientia | Maintains: Overweight | $12 → $10 | $5.22 | +91.57% | 2 | Oct 17, 2023 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $2 → $1 | $1.30 | -23.08% | 2 | Aug 10, 2023 | |
| PRLD Prelude Therapeutics | Maintains: Equal-Weight | $7 → $5 | $5.99 | -16.53% | 4 | Aug 4, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $31 → $34 | $24.63 | +38.04% | 2 | Jul 26, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $80 | $40.15 | +99.25% | 1 | Nov 30, 2022 | |
| NEXI NexImmune | Maintains: Overweight | $175 → $50 | $1.38 | +3,523.19% | 2 | Aug 16, 2022 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $14 → $8 | $0.96 | +733.07% | 2 | Aug 5, 2022 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | $30 | $24.44 | +22.75% | 1 | Jul 28, 2022 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $7 → $3.5 | $1.42 | +146.48% | 3 | Jul 7, 2022 | |
| ILMN Illumina | Maintains: Underweight | n/a | $117.30 | - | 1 | Aug 6, 2021 | |
| AGIO Agios Pharmaceuticals | Upgrades: Overweight | n/a | $48.50 | - | 2 | Oct 22, 2020 | |
| XNCR Xencor | Initiates: Underweight | n/a | $21.27 | - | 1 | Mar 4, 2020 | |
| NKTR Nektar Therapeutics | Initiates: Overweight | n/a | $1.37 | - | 1 | Mar 4, 2020 | |
| EDIT Editas Medicine | Upgrades: Buy | n/a | $5.57 | - | 1 | Jan 23, 2018 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Buy | n/a | $57.57 | - | 1 | Jan 23, 2018 | |
| AFMD Affimed | Initiates: Buy | $70 | $5.10 | +1,272.55% | 1 | Jul 14, 2017 |
Revolution Medicines
Jul 18, 2024
Maintains: Overweight
Price Target: $52 → $54
Current: $45.56
Upside: +18.53%
Nurix Therapeutics
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $21.04
Upside: +47.34%
Arcus Biosciences
Jul 8, 2024
Maintains: Overweight
Price Target: $35 → $25
Current: $14.98
Upside: +66.89%
Replimune Group
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $10.48
Upside: +62.21%
Biomea Fusion
Jun 7, 2024
Downgrades: Equal-Weight
Price Target: $30 → $5
Current: $5.46
Upside: -8.42%
Tango Therapeutics
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $9.85
Upside: +31.98%
MacroGenics
May 10, 2024
Maintains: Overweight
Price Target: $25 → $14
Current: $5.50
Upside: +154.55%
Relay Therapeutics
May 10, 2024
Upgrades: Overweight
Price Target: $15
Current: $9.06
Upside: +65.56%
Blueprint Medicines
May 3, 2024
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $113.69
Upside: -34.03%
Exelixis
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $22.96
Upside: +8.89%
TScan Therapeutics
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $7.18
Upside: +25.35%
Arvinas
Feb 29, 2024
Maintains: Overweight
Price Target: $26 → $60
Current: $29.52
Upside: +103.25%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $9.43
Upside: +133.30%
SpringWorks Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $36.87
Upside: +70.87%
Fate Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $5.40
Upside: +85.19%
Exscientia
Oct 17, 2023
Maintains: Overweight
Price Target: $12 → $10
Current: $5.22
Upside: +91.57%
Adaptimmune Therapeutics
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.30
Upside: -23.08%
Prelude Therapeutics
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $5.99
Upside: -16.53%
Syndax Pharmaceuticals
Jul 26, 2023
Maintains: Overweight
Price Target: $31 → $34
Current: $24.63
Upside: +38.04%
Immunocore Holdings
Nov 30, 2022
Initiates: Overweight
Price Target: $80
Current: $40.15
Upside: +99.25%
NexImmune
Aug 16, 2022
Maintains: Overweight
Price Target: $175 → $50
Current: $1.38
Upside: +3,523.19%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.96
Upside: +733.07%
Bicycle Therapeutics
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $24.44
Upside: +22.75%
CytomX Therapeutics
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.42
Upside: +146.48%
Illumina
Aug 6, 2021
Maintains: Underweight
Price Target: n/a
Current: $117.30
Upside: -
Agios Pharmaceuticals
Oct 22, 2020
Upgrades: Overweight
Price Target: n/a
Current: $48.50
Upside: -
Xencor
Mar 4, 2020
Initiates: Underweight
Price Target: n/a
Current: $21.27
Upside: -
Nektar Therapeutics
Mar 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.37
Upside: -
Editas Medicine
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $5.57
Upside: -
CRISPR Therapeutics AG
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $57.57
Upside: -
Affimed
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $5.10
Upside: +1,272.55%